Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.


We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus. Intervention included randomization to 25 mg of hydrochlorothiazide or 100 mg of… (More)
DOI: 10.1161/HYPERTENSIONAHA.109.139592

3 Figures and Tables


  • Presentations referencing similar topics